Allergan plc (AGN) Forms $186.93 Double Bottom; Home Bancorp, Inc. (HBCP) Covered By 0 Bulls

Among 2 analysts covering Home Bancorp (NASDAQ:HBCP), 0 have Buy rating, 0 Sell and 2 Hold. Therefore 0 are positive. Home Bancorp had 4 analyst reports since August 13, 2015 according to SRatingsIntel. Raymond James downgraded Home Bancorp, Inc. (NASDAQ:HBCP) on Wednesday, July 26 to “Market Perform” rating. Raymond James initiated the shares of HBCP in report on Wednesday, September 30 with “Outperform” rating. The firm has “Hold” rating by Sandler O’Neill given on Wednesday, October 18. The firm earned “Buy” rating on Thursday, August 13 by Zacks. See Home Bancorp, Inc. (NASDAQ:HBCP) latest ratings:

18/10/2017 Broker: Sandler O’Neill Rating: Hold New Target: $46 Maintain

Allergan plc (AGN) formed double bottom with $171.98 target or 8.00% below today’s $186.93 share price. Allergan plc (AGN) has $62.17 billion valuation. The stock decreased 0.10% or $0.19 during the last trading session, reaching $186.93. About 1.97 million shares traded. Allergan plc (NYSE:AGN) has declined 3.42% since January 29, 2017 and is downtrending. It has underperformed by 20.12% the S&P500.

The stock decreased 0.45% or $0.19 during the last trading session, reaching $42.14. About 5,005 shares traded. Home Bancorp, Inc. (NASDAQ:HBCP) has risen 24.80% since January 29, 2017 and is uptrending. It has outperformed by 8.10% the S&P500.

Home Bancorp, Inc. operates as the holding firm for Home Bank, National Association that provides various banking services and products in Louisiana. The company has market cap of $313.76 million. It offers deposits products, including interest-bearing and noninterest-bearing checking, money market, savings, and certificates of deposit accounts. It has a 16.99 P/E ratio. The firm also provides various loan products, such as one-to-four-family first mortgage loans, home equity loans and lines, commercial real estate loans, construction and land loans, multi-family residential loans, commercial and industrial loans, and consumer loans.

Among 26 analysts covering Allergan Inc. (NYSE:AGN), 17 have Buy rating, 0 Sell and 9 Hold. Therefore 65% are positive. Allergan Inc. has $400 highest and $185.0 lowest target. $264.81’s average target is 41.66% above currents $186.93 stock price. Allergan Inc. had 103 analyst reports since July 29, 2015 according to SRatingsIntel. The firm has “Hold” rating by Cantor Fitzgerald given on Monday, August 21. As per Friday, August 19, the company rating was upgraded by Mizuho. RBC Capital Markets maintained Allergan plc (NYSE:AGN) rating on Monday, June 12. RBC Capital Markets has “Buy” rating and $28400 target. The company was maintained on Thursday, January 4 by RBC Capital Markets. The firm has “Equal-Weight” rating by Barclays Capital given on Monday, October 31. The stock has “Hold” rating by Edward Jones on Wednesday, October 18. The stock of Allergan plc (NYSE:AGN) earned “Outperform” rating by Leerink Swann on Tuesday, July 28. Mizuho maintained the shares of AGN in report on Friday, August 5 with “Neutral” rating. Citigroup maintained Allergan plc (NYSE:AGN) on Thursday, October 19 with “Buy” rating. Mizuho maintained Allergan plc (NYSE:AGN) on Tuesday, October 11 with “Buy” rating.

Investors sentiment decreased to 0.33 in Q3 2017. Its down 0.05, from 0.38 in 2017Q2. It turned negative, as 3 investors sold Allergan plc shares while 3 reduced holdings. 0 funds opened positions while 2 raised stakes. 54,287 shares or 4.93% less from 57,100 shares in 2017Q2 were reported. Frontier Investment Communications invested in 30,139 shares or 0.51% of the stock. Cubic Asset Management Limited Liability Corp accumulated 0.13% or 2,311 shares. Moreover, Gemmer Asset Mngmt Lc has 0.01% invested in Allergan plc (NYSE:AGN). Amer Rech & Management holds 0% of its portfolio in Allergan plc (NYSE:AGN) for 33 shares. Dowling Yahnke Ltd Limited Liability Company owns 2,086 shares. Connors Investor Svcs has invested 0.03% in Allergan plc (NYSE:AGN). Mitchell Mcleod Pugh And Williams Incorporated has 0.6% invested in Allergan plc (NYSE:AGN) for 3,975 shares. Eqis holds 7,802 shares or 0.09% of its portfolio. 6,825 were reported by Grassi Management.

Analysts await Allergan plc (NYSE:AGN) to report earnings on February, 14. They expect $4.73 earnings per share, up 21.28% or $0.83 from last year’s $3.9 per share. AGN’s profit will be $1.57B for 9.88 P/E if the $4.73 EPS becomes a reality. After $4.15 actual earnings per share reported by Allergan plc for the previous quarter, Wall Street now forecasts 13.98% EPS growth.